EMA’s CHMP Issues Negative Opinion on Lilly’s Kisunla for Alzheimer’s
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Eli Lilly
Eli Lilly Launches Kisunla in China for Early Alzheimer’s Treatment
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has officially launched Kisunla (donanemab) in...
Laekna Submits Revised Protocol for LAE102 Obesity Trial with Eli Lilly
Sino-US biotech Laekna Therapeutics (HKG: 2105) announced the submission of a revised clinical protocol to...
Eli Lilly Launches Lilly Gateway Laboratory in China to Boost Biotech Innovation
US major Eli Lilly & Co., (NYSE: LLY) has announced the opening of the Lilly...
NovoCare Pharmacy Offers Reduced-Cost Wegovy for Cash-Paying Patients
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced the launch of NovoCare Pharmacy, a direct-to-patient...
Boehringer Ingelheim Appeals CNIPA’s Invalidation of Jardiance Patents
The Intellectual Property Court of the Supreme People’s Court of China issued a notice, holding...
Magnet Biomedicine and Eli Lilly Partner on Molecular Glue Therapeutics
US-based molecular glue specialist Magnet Biomedicine has entered into a collaboration and license agreement with...
Eli Lilly to Establish Four New US Pharma Manufacturing Sites
US major Eli Lilly & Co. (NYSE: LLY) announced plans to establish four new pharmaceutical...
Eli Lilly Launches New Zepbound Doses with Lower Prices for Self-Pay Patients
Eli Lilly & Co. (NYSE: LLY) announced the launch of 7.5 mg and 10 mg...
Eli Lilly Acquires Organovo’s FXR Program for Inflammatory Bowel Disease
US-based Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical-stage biotech focused on inflammatory bowel disease (IBD),...
Gan & Lee Pharmaceuticals Doses First Patient in GZR4 Phase III Study for Diabetes
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...
Hengrui’s Vunakizumab Receives NMPA Approval for nr-axSpA Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received another clinical trial...
Eli Lilly Expands Collaboration with AdvanCell on Targeted Alpha Therapies for Cancer
Eli Lilly & Co. (NYSE: LLY) has expanded its collaboration with Australia-based AdvanCell, a clinical-stage...
Eli Lilly Licenses OliX Pharma’s OLX75016 for MASH and Cardiometabolic Diseases
Eli Lilly & Co. (NYSE: LLY) has signed a licensing agreement with OliX Pharmaceuticals, Inc....
Eli Lilly’s Q4 Sales Soar 45% to $13.53B on Strength of GLP-1 Drugs
Eli Lilly & Co. (NYSE: LLY) reported a robust finish to 2024, with Q4 revenues...
Eli Lilly and Merck Launch Consortium for Innovative Drug Manufacturing
US-based Eli Lilly and Company (NYSE: LLY) and Merck & Co. Inc. (NYSE: MRK) have...
FDA Lifts Clinical Hold on Sanofi’s Cialis Over-the-Counter Trial
France-based Sanofi’s (NASDAQ: SNY, EPA: SAN) Consumer Healthcare unit Opella has announced that the US...
Chongqing Genrix’s Xeligekimab Approved for Ankylosing Spondylitis by NMPA
China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443) has announced receiving approval from the...
Eli Lilly’s Omvoh Approved by FDA for Crohn’s Disease Treatment
US major Eli Lilly and Company (NYSE: LLY) has announced receiving marketing approval from the...
Eli Lilly to Acquire Scorpion Therapeutics’ STX-478 for $2.5B
US-based pharmaceutical giant Eli Lilly and Company (NYSE: LLY) is set to acquire STX-478 from...